Publication

Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF

Publications associées (29)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently ne ...

TAYLOR & FRANCIS INC2023

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Agnieszka Alicja Chryplewicz

Glioblastoma (GBM) is the most frequent and highly malignant form of brain cancer. New therapeutic regimens are urgently needed as GBM patients present with a minimal response to currently-approved therapies. The goal of this project is to identify new the ...

EPFL2023

Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth

Mauro Delorenzi, Stefanie Siegert, Pascale Anderle Pedone, Nadine Fournier, Sina Nassiri, François Renevey, Michele De Palma, Mario Leonardo Squadrito, Simone Ragusa

Stem and progenitor cells residing in the intestinal crypts drive the majority of colorectal cancers (CRCs), yet vascular contribution to this niche remains largely unexplored. Vascular endothelial growth factor A (VEGFA) is a key driver of physiological a ...

Springernature2022

Immunosuppressive roles of Activin-A in melanoma and characterization of its precursor cleavage

Katarina Pinjusic

Activin-A, a transforming growth factor ê µ family member, is a pleiotropic cytokine with diverse functions in development, fertility, adult tissue homeostasis, and aging. Accordingly, deregulation of Activin-A signaling has been associated with many patho ...

EPFL2022

BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

Li Tang, Bing Feng, Thomas Gruber

Background The use of intralesional Mycobacterium bovis BCG (intralesional live BCG) for the treatment of metastatic melanoma resulted in regression of directly injected, and occasionally of distal lesions. However, intralesional-BCG is less effective in p ...

BMJ PUBLISHING GROUP2022

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation

Andrea Ablasser

Solid cancers exhibit a dynamic balance between cell death and proliferation ensuring continuous tumour maintenance and growth(1,2). Increasing evidence links enhanced cancer cell apoptosis to paracrine activation of cells in the tumour microenvironment in ...

NATURE PORTFOLIO2022

Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy

Yuqing Xie

In the past decades, breakthroughs in cancer immunotherapy have led to unprecedented clinical responses in patients with advanced-stage cancers that would otherwise be fatal. However, treatment of many solid organ malignancies with highly immunosuppressive ...

EPFL2022

The role of eosinophils in breast cancer

Luisa Spisak

Eosinophils are granulocytes and belong to the innate arm of immunity. Eosinophils can be in different basal or activation states and depending on which type of activation is applied, they exert different effector functions. These multi-functional cells ha ...

EPFL2022

Dendritic cell cross-dressing and tumor immunity

Michele De Palma, Amaia Martinez Usatorre

In addition to direct and cross-presentation, dendritic cells (DCs) can present tumor antigens (TAs) to T cells via a hitherto poorly understood mechanism called "cross-dressing." DC cross-dressing involves the acquisition of preformed peptide-major histoc ...

WILEY2022